Barriers to Implementing ctDNA Testing
Panelists analyze observed obstacles to implementing routine circulating tumor DNA testing as a standard of care, while offering strategies to overcome these challenges.
EP: 1.Overview of colorectal cancer and its management
EP: 2.Background on Colorectal Cancer Screening and its Role in Patient Care
EP: 3.Circulating Tumor DNA Detection Techniques
EP: 4.Describing the Value of ctDNA in Clinical Practice
EP: 5.Clinical study of ctDNA-based MRD detection and INTERCEPT program update
EP: 6.Recent findings from BESPOKE
EP: 7.Incorporating ctDNA-Based MRD Testing and Study Findings Into Clinical Practice
EP: 8.Key Considerations for Selection of ctDNA Detection Methods
EP: 9.Clinical Utility of ctDNA Testing
EP: 10.Barriers to Implementing ctDNA Testing
EP: 11.ctDNA Testing in a CRC Clinical Scenario
EP: 12.ctDNA to Inform Adjuvant Therapy and the CIRCULATE Trial
EP: 13.Interpreting and Communicating ctDNA Results
EP: 14.Addressing Gaps in ctDNA Testing
EP: 15.Exploring the Future of ctDNA and Novel Treatment Strategies
- What are some barriers that have been observed to implementing routine standard-of-care ctDNA testing?
- Do barriers differ between academic and community settings?
- Do you have any practical tips to navigate these barriers to implementation?
Prolaris in Practice: Guiding ADT Benefits, Clinical Application, and Expert Insights From ACRO 2025
April 15th 2025Steven E. Finkelstein, MD, DABR, FACRO discuses how Prolaris distinguishes itself from other genomic biomarker platforms by providing uniquely actionable clinical information that quantifies the absolute benefit of androgen deprivation therapy when added to radiation therapy, offering clinicians a more precise tool for personalizing prostate cancer treatment strategies.
CCR Scores and Beyond: Precision Strategies for Treatment Intensification in Prostate Cancer
April 15th 2025Alvaro Martinez, MD discusses how emerging genomic risk stratification tools such as the clinical cell-cycle risk (CCR) score are transforming personalized prostate cancer treatment by enabling more nuanced assessments of metastasis risk and treatment intensification strategies beyond traditional NCCN risk groupings.
